Page last updated: 2024-11-04

aminosalicylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Aminosalicylic acid (PAS) is an anti-tuberculosis medication. It was once a first-line treatment for tuberculosis, but has now largely been replaced by more effective and less toxic drugs. It was first synthesized in the 1940s and its mechanism of action is thought to be through inhibiting the synthesis of mycolic acids, which are essential components of the cell wall of Mycobacterium tuberculosis. PAS can be administered orally and is generally well-tolerated, but side effects can include gastrointestinal upset, liver toxicity, and hypersensitivity reactions. It is still sometimes used in combination with other drugs for the treatment of multidrug-resistant tuberculosis. Research into PAS has largely been superseded by the development of more effective drugs, but it continues to be studied in some contexts, such as in combination therapies for multidrug-resistant tuberculosis and as a potential agent for the treatment of other bacterial infections.'
```

Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4649
CHEMBL ID1169
CHEBI ID27565
SCHEMBL ID2262
MeSH IDM0000970

Synonyms (179)

Synonym
AC-12894
BIDD:GT0175
aminosalicylic
paser granules
ai3-50142
aminosalyl
hellipidyl
pascorbic
einecs 200-613-5
helipidyl
brn 0473071
pas (van)
kyselina p-aminosalicylova [czech]
aminosalicylic acid [usp]
hsdb 3203
MLS001148121
AB00051913-20
pask
salicyclic acid, 4-amino-
pasmed
3-hydroxy-4-carboxyaniline
pasem
4-amino-2-hydroxybenzoic acid
pasnodia
parasalindon
kyselina p-aminosalicylova
benzoic acid, 4-amino-2-hydroxy-
entepas
gabbropas
deapasil
pas-c
salicylic acid, 4-amino-
a 1909
apas
nsc2083
apacil
osacyl
2-hydroxy-4-aminobenzoic acid
aminox
pasa
sanipriol-4
pasolac
pasara
p-aminosalicylic acid
pasdium
parasalicil
rezipas
aminopar
pasalon
wln: zr cq dvq
PAS ,
nsc-2083
aminosalicylic acid
pamisyl
propasa
paramycin
para-pas
pas (acid)
pamacyl
nih 2939
nsc 2083
parasal
sanipirol-4
MLS000069418 ,
DIVK1C_000350
KBIO1_000350
aminosalicylic acid (usp)
paser (tn)
pamisyl (tn)
D00162
SPECTRUM_000042
SPECTRUM5_000804
IDI1_000350
.gamma.-aminosalicylate
4-amino-2-hydroxy-benzoic acid
p-aminosalicylic acid standard
BSPBIO_001834
inchi=1/c7h7no3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9h,8h2,(h,10,11
4-amino,2-hydroxy-benzoic acid
C02518
4-aminosalicylate
65-49-6
4-aminosalicylic acid
4-aminosalicylic acid, 99%
para-aminosalicylic acid
DB00233
para-amino salicylic acid
paser
CHEBI:27565 ,
MLS000069579 ,
isonicotinic acid hydrazide p-aminosalicylate salt
smr000058830
smr000059110
KBIO2_000422
KBIO3_001334
KBIO2_002990
KBIOGR_000590
KBIO2_005558
KBIOSS_000422
SPECTRUM2_000001
SPECTRUM4_000145
NINDS_000350
SPBIO_000001
SPECTRUM3_000297
NCGC00018110-01
HMS2093L14
HMS2090I07
A0420
KUC106682N
ksc-11-207-13
CHEMBL1169
aminosalicylate
HMS501B12
AKOS000121200
NCGC00018110-03
NCGC00018110-02
NCGC00018110-04
p.a.s
unii-5b2658e0n2
4-14-00-01967 (beilstein handbook reference)
5b2658e0n2 ,
granupas
STL163955
amino-pas
4-asa
HMS2236I04
CCG-39969
FT-0617609
FT-0689453
S5211
HMS3371A17
aminosalicylic acid [hsdb]
aminosalicylic acid [usp monograph]
neopasalate component aminosalicylic acid
aminosalicylic acid [vandf]
aminosalicylic acid [mart.]
mesalazine impurity e [ep impurity]
aminosalicylic acid component of neopasalate
aminosalicylic acid [who-dd]
p-aminosalicylic acid [mi]
aminosalicylic acid [usp-rs]
aminosalicylic acid [orange book]
SCHEMBL2262
4-aminosalicyclic acid
4-amino salicylic acid
p-amino salicylic acid
para-amino-salicyclic acid
Q-200437
4-aminosalicylicacid
4-azanyl-2-oxidanyl-benzoic acid
bdbm48319
cid_11988145
OPERA_ID_614
DTXSID2022591
mfcd00007789
benzoic acid, 4-aminohydroxy-
F2191-0245
Z90121065
sr-01000002990
aminosalicylic acid, united states pharmacopeia (usp) reference standard
4-aminosalicylic acid, vetec(tm) reagent grade, 99%
4-aminosalicylic acid, pharmaceutical secondary standard; certified reference material
SR-01000002990-6
SR-01000002990-4
SBI-0051279.P004
SBI-0051279.P003
HMS3715M08
SY001079
CS-W023102
BCP18565
4-amino-2-hydroxobenzoic acid
Q229924
HY-I0447
AS-11043
AMY31099
P17508
PB47849
EN300-18730
para-aminosalicylic acid;aminosalicylic acid;4-aminosalicylate

Research Excerpts

Overview

Para-aminosalicylic acid (PAS) is an important second-line antibiotic for treating multidrug-resistant tuberculosis (MDR-TB) 4-Aminosalicyric acid seems to be a suitable drug for improving the clinical symptoms of ulcerative proctitis.

ExcerptReferenceRelevance
"Para-aminosalicylic acid (PAS) is an antibiotic that was largely used for the multi-therapy of tuberculosis in the twentieth century. "( A combination screening to identify enhancers of para-aminosalicylic acid against Mycobacterium tuberculosis.
Brodin, P; Choi, I; de Almeida Falcão, VC; Delorme, V; Heo, J; Jang, J; Kim, K; Koh, D; Kwon, D; Lee, H; Shum, D; Woo, M; Wood, C, 2022
)
1.48
"p-Aminosalicylic acid (PAS) is an important second-line antibiotic for treating multidrug-resistant tuberculosis (MDR-TB). "( Multi-omics comparisons of p-aminosalicylic acid (PAS) resistance in folC mutated and un-mutated Mycobacterium tuberculosis strains.
Chen, T; Guo, H; Li, H; Li, Z; Wang, X; Wei, W; Yan, H; Zeng, J; Zhang, X; Zhao, J; Zhou, L; Zhou, Y, 2019
)
1.53
"p-Aminosalicylic acid (PAS) is an important compound for treating multidrug-resistant tuberculosis (TB). "( Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012.
Dai, G; Huang, H; Jin, Q; Liu, L; Zhang, X; Zhang, Y, 2015
)
1.42
"4-Aminosalicylic acid seems to be a suitable drug for improving the clinical symptoms of ulcerative proctitis."( Experience with topical administration of 4-aminosalicylic acid in ulcerative colitis.
Karacsony, G; Nagy, F; Varro, V, 1989
)
1.1
"4-Aminosalicylic acid enemas are a safe and effective means of treating left-sided ulcerative colitis."( Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial.
Beck, LS; Ginsberg, AL; McIntosh, TM; Nochomovitz, LE, 1988
)
1.09

Effects

4-Aminosalicylic acid (4-ASA) has been suggested as an effective treatment for both active and quiescent ulcerative colitis. It was tested whether this drug possesses any influence on the 5-lipoxygenase activity in human neutrophils.

ExcerptReferenceRelevance
"4-Aminosalicylic acid has the potential for use in the treatment of diseases of the colon."( Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules.
Basit, AW; Ell, PJ; Newton, JM; Tuleu, C; Waddington, WA, 2002
)
1.35
"4-Aminosalicylic acid (4-ASA) has been suggested as an effective treatment for both active and quiescent ulcerative colitis. "( Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
Howaldt, S; Raedler, A; Schreiber, S, 1994
)
1.47
"As 4-aminosalicylic acid has been claimed to be beneficial in the topical treatment of ulcerative colitis, it was tested whether this drug possesses any influence on the 5-lipoxygenase activity in human neutrophils in vitro or whether it acts as a radical scavenger."( 4-Aminosalicylic acid, in contrast to 5-aminosalicylic acid, has no effect on arachidonic acid metabolism in human neutrophils, or on the free radical 1,1-diphenyl-2-picrylhydrazyl.
Ahnfelt-Rønne, I; Nielsen, OH, 1988
)
1.45

Actions

ExcerptReferenceRelevance
"Para-aminosalicylic acid granules produce adequate serum concentrations and appear to be safe."( Pharmacokinetic evaluation of para-aminosalicylic acid granules.
Berning, SE; Henshaw, TL; Huitt, GA; James, GT; Nitta, AT; Peloquin, CA,
)
0.92

Toxicity

Fluoroquinolones, clofazimine, and bedaquiline had the lowest incidence of adverse events leading to permanent drug discontinuation. Second-line injectable drugs, aminosalicylic acid, and linezolid had the highest incidence.

ExcerptReferenceRelevance
"Oral 5-ASA appears to be safe for the management of inflammatory bowel disease during pregnancy."( Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course.
Greenberg, GR; Habal, FM; Hui, G, 1993
)
0.74
" The free acid compounds were less toxic than their corresponding salts."( Comparative cytotoxicity of 5-aminosalicylic acid (mesalazine) and related compounds in different cell lines.
Dierickx, PJ; Janssen, L; Noble, E, 1997
)
0.59
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" We investigated the toxic effects of MnCl2 in an immortalized rat brain endothelial cell line (RBE4) and the protective effects of the radical scavenging aminosalicylic acids, 5-aminosalicylic acid (5-ASA) and 4-aminosalicylic acid (4-PAS)."( Comparison between 5-aminosalicylic acid (5-ASA) and para-aminosalicylic acid (4-PAS) as potential protectors against Mn-induced neurotoxicity.
Aschner, M; Batoreu, MC; Marreilha dos Santos, AP; Santos, D, 2013
)
0.91
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" The characteristics of RMR-TB were compared with those with adverse events to rifampin (RAE-TB)."( Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017
)
0.46
" However, KFXL combined with ASA did not increase the adverse event incidence [RR = 0."( Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Cai, QQ; Chen, MY; Chen, XL; Li, DT; Li, HB; Qiu, ZW; Tang, HM, 2018
)
0.73
"KFXL combined with ASA has good therapeutic effect for UC and might be a safe approach in managing UC."( Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Cai, QQ; Chen, MY; Chen, XL; Li, DT; Li, HB; Qiu, ZW; Tang, HM, 2018
)
0.73
" Probiotics such as bifid triple viable (BTV) could reduce drug-induced adverse reactions and has a good clinical effect on UC."( Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Cai, QQ; Chen, MY; Chen, XL; Li, HB; Qiu, ZW; Tang, HM; Zhuang, KH, 2019
)
0.77
"0005]; and adverse effect rate [RR = 0."( Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Cai, QQ; Chen, MY; Chen, XL; Li, HB; Qiu, ZW; Tang, HM; Zhuang, KH, 2019
)
0.77
"BTV plus ASA has positive therapeutic effects on UC, and it might be a safe way to treat UC."( Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Cai, QQ; Chen, MY; Chen, XL; Li, HB; Qiu, ZW; Tang, HM; Zhuang, KH, 2019
)
0.77
" These drugs are associated with numerous adverse events that can cause severe morbidity, such as deafness, and in some instances can lead to death."( Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020
)
0.56
"We did a meta-analysis using individual-level patient data that were obtained from studies that reported adverse events that resulted in permanent discontinuation of anti-tuberculosis medications."( Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020
)
0.56
" Using meta-analysis of proportions, drugs with low risks of adverse event occurrence leading to permanent discontinuation included levofloxacin (1·3% [95% CI 0·3-5·0]), moxifloxacin (2·9% [1·6-5·0]), bedaquiline (1·7% [0·7-4·2]), and clofazimine (1·6% [0·5-5·3])."( Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020
)
0.56
"Fluoroquinolones, clofazimine, and bedaquiline had the lowest incidence of adverse events leading to permanent drug discontinuation, whereas second-line injectable drugs, aminosalicylic acid, and linezolid had the highest incidence."( Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Ahmad, N; Baghaei, P; Barkane, L; Benedetti, A; Brode, SK; Brust, JCM; Campbell, JR; Chang, VWL; Falzon, D; Guglielmetti, L; Isaakidis, P; Kempker, RR; Kipiani, M; Kuksa, L; Lan, Z; Lange, C; Laniado-Laborín, R; Menzies, D; Nahid, P; Rodrigues, D; Singla, R; Udwadia, ZF, 2020
)
0.75

Pharmacokinetics

ExcerptReferenceRelevance
"(a) Single-dose pharmacokinetic study in healthy volunteers; (b) Day-1 and day-8 pharmacokinetic comparison in patients with multidrug-resistant tuberculosis (MDR-TB)."( Pharmacokinetic evaluation of para-aminosalicylic acid granules.
Berning, SE; Henshaw, TL; Huitt, GA; James, GT; Nitta, AT; Peloquin, CA,
)
0.41
"To determine the effect of a high-fat meal, orange juice, and antacids on absorption of a single oral dose of cycloserine and to estimate its population pharmacokinetic parameters."( Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids.
Adam, RD; Childs, JM; Nix, DE; Peloquin, CA; Zhu, M, 2001
)
0.31
" No other statistically significant differences were observed for Cmax and area under the curve from time zero to infinity across the four treatments."( Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids.
Adam, RD; Childs, JM; Nix, DE; Peloquin, CA; Zhu, M, 2001
)
0.31
" Pharmacokinetic data analysis was performed with WinNonlin using noncompartmental methods and a one-compartmental model."( Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions.
Adam, RD; Nix, DE; Peloquin, CA; Singleton, MD; Zhu, M, 2001
)
0.61
" A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index."( Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014
)
0.71
" To evaluate the pharmacokinetic (PK) characteristics of clinically relevant, multidrug treatment regimens and to improve the feasibility of TDM, we conducted an open-label, multiple-dosing study with 16 healthy subjects who were divided into two groups."( Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.
Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS, 2015
)
0.42
" It is important to generate pharmacokinetic studies of drugs used to treat MDR TB in children in different settings, which would provide useful information on the adequacy of drug doses."( Pharmacokinetics of Second-Line Anti-Tubercular Drugs.
Ramachandran, G, 2019
)
0.51
" A population pharmacokinetic model was developed describing PAS pharmacokinetics in children receiving routine RR-TB treatment."( Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
Chirehwa, M; Denti, P; Donald, PR; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Mao, J; McIlleron, H; Norman, J; Schaaf, HS; van der Laan, LE; Wiesner, L; Winckler, JL, 2022
)
0.97

Compound-Compound Interactions

ExcerptReferenceRelevance
"To systematically evaluate the clinical efficacy and safety of Kangfuxin liquid (KFXL) combined with aminosalicylic acid (ASA) in treating ulcerative colitis (UC)."( Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Cai, QQ; Chen, MY; Chen, XL; Li, DT; Li, HB; Qiu, ZW; Tang, HM, 2018
)
0.95
"The PubMed, Cochrane Library, Embase, CBM, Wan fang, the Chinese Scientific Journal Database (VIP), and Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched for randomized controlled trials of KFXL combined with ASA for UC from the inception dates to March 3, 2017."( Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Cai, QQ; Chen, MY; Chen, XL; Li, DT; Li, HB; Qiu, ZW; Tang, HM, 2018
)
0.73
" Compared with ASA alone, KFXL combined with ASA significantly improved the clinical effectiveness rate [RR = 1."( Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Cai, QQ; Chen, MY; Chen, XL; Li, DT; Li, HB; Qiu, ZW; Tang, HM, 2018
)
0.73
"KFXL combined with ASA has good therapeutic effect for UC and might be a safe approach in managing UC."( Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Cai, QQ; Chen, MY; Chen, XL; Li, DT; Li, HB; Qiu, ZW; Tang, HM, 2018
)
0.73
"We conducted a meta-analysis to evaluate the effect of probiotic combined with aminosalicylic on induction remission maintenance treatment of ulcerative colitis (UC)."( Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial.
Jiang, Z; Peng, L; Wang, A; Zhong, Y, 2019
)
0.82

Bioavailability

Para-Aminosalicylic acid (PAS) is an important second-line agent for treating drug-resistant Mycobacterium tuberculosis. It has moderate bioavailability and rapid clearance that necessitate high daily doses of up to 12 g per day.

ExcerptReferenceRelevance
" In contrast to these results, compounds such as urea and amitrole, which remain completely nonionized over the pH range studied, showed no change in absorption rate when the pH was varied."( Lung pH and pulmonary absorption of nonvolatile drugs in the rat.
Less, MJ; Schanker, LS,
)
0.13
"To determine the bioavailability and renal elimination of para-aminosalicylic acid (PAS) and its inactive metabolite acetyl-para-aminosalicylic acid (AcPAS) from a new PAS formulation."( Pharmacokinetic evaluation of para-aminosalicylic acid granules.
Berning, SE; Henshaw, TL; Huitt, GA; James, GT; Nitta, AT; Peloquin, CA,
)
0.65
"To determine the pharmacokinetics and relative bioavailability of para-aminosalicylic acid (PAS) granules."( Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions.
Adam, RD; Nix, DE; Peloquin, CA; Singleton, MD; Zhu, M, 2001
)
0.85
"After the completion of the treatment course, the negative sputum conversion rate in V+D+M treatment protocol group was 84%, significantly higher than that in the control group (42%); the former group showed a focal absorption rate and pulmonary cavity closure rate of 83% and 66%, which were 33% and 26% respectively in the latter."( [Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Li, SM; Xing, BC; Zheng, XM, 2004
)
0.32
" This study was conducted to explore issues relating to bioavailability in the presence of food, orange juice, and antacid."( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004
)
0.32
" The pharmacokinetics of clofazimine were assessed using individual- and population-based methods and relative bioavailability compared to fasting administration was determined."( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004
)
0.32
"Administration of clofazimine with a high fat meal provides the greatest bioavailability, however, bioavailability is associated with high inter- and intra-subject variability."( Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.
Adam, RD; Auclair, B; Godo, PG; Krueger, TS; Nix, DE; Peloquin, CA, 2004
)
0.32
" Enhancement of in vivo performance was further demonstrated: a 10-fold increase in bioavailability was achieved for the cocrystal in comparison to the neat nanocrystalline telaprevir and it was found to be not statistically different from the lead amorphous spray-dried formulation."( Cocrystalline Solids of Telaprevir with Enhanced Oral Absorption.
Hurrey, M; Hurter, P; Johnston, SC; Kadiyala, I; Rao, BG; Stavropoulos, K; Topp, EM; Zhang, Y, 2015
)
0.42
" These guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNFα antagonists, vedolizumab, and combination therapies."( Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Annese, V; Ardizzone, S; Armuzzi, A; Biancone, L; Calabrese, E; Caprioli, F; Castiglione, F; Comberlato, M; Cottone, M; D'Incà, R; Danese, S; Daperno, M; Frieri, G; Fries, W; Gionchetti, P; Kohn, A; Latella, G; Meucci, G; Milla, M; Orlando, A; Papi, C; Petruzziello, C; Riegler, G; Rizzello, F; Saibeni, S; Scribano, ML; Vecchi, M; Vernia, P, 2017
)
0.46
" aureus, (iii) larger oral absorption and bioavailability (2."( Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating.
Bolas-Fernandez, F; Dea-Ayuela, MA; Galiana, C; Healy, AM; Mugheirbi, NA; O'Connell, P; Serrano, DR; Walsh, D; Worku, ZA, 2018
)
0.48
"The final optimized model included the addition of variability in bioavailability and allometric scaling with body weight on disposition parameters."( Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Abulfathi, AA; Assawasuwannakit, P; Diacon, AH; Donald, PR; Reuter, H; Svensson, EM, 2020
)
0.81
" para-Aminosalicylic acid (PAS), an important second-line agent for treating drug-resistant Mycobacterium tuberculosis, has moderate bioavailability and rapid clearance that necessitate high daily doses of up to 12 g per day, which in turn causes severe gastrointestinal disturbances presumably by disruption of gut microbiota and host epithelial cells."( Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Aldrich, CC; Baughn, AD; Boshoff, HIM; Dartois, V; Hegde, PV; Howe, MD; Jia, Z; Pan, Y; Remache, B; Sharma, S; Zimmerman, MD, 2022
)
1.43

Dosage Studied

5-Aminosalicylic acid (5-ASA) is the active component of Salazopyrin. It induces a prompt and excellent improvement, when administered as high dosage enema, in patients suffering from active ulcerative colitis.

ExcerptRelevanceReference
" The 350 children were treated with 2 drugs, during the early years isoniazid and PAS and in the past 3 years isoniazid and rifampicin in standard dosage for either 12 or 18 months."( Occult tuberculous infection in children.
Fox, TG, 1977
)
0.26
" In the treatements with PAS Na and PRA the analysis of the frequencies of the cell carring chromosomal aberrations and of the chromosomal lesion types indicated a dose-response correlation."( Cytogenetic effect of some anti-tuberculosis drugs in vitro.
Georgian, L; Roman, IC, 1977
)
0.26
" Incubation with higher concentrations of the drugs revealed a dose-response effect on binding with complete inhibition by 100 mM 4ASA and 10 mM olsalazine, and lesser degrees of inhibition by 100 mM 5ASA, N-acetyl-5ASA, and N-acetyl-4ASA."( Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
Aronson, JK; Crotty, B; Jewell, DP; Rosenberg, WM, 1992
)
0.28
" A pharmacokinetic comparison of polymer and SASP showed similar deliveries of 5-ASA and metabolites to the lower bowel, blood, and urine of orally dosed rats."( A polymeric drug for treatment of inflammatory bowel disease.
Brown, JP; McGarraugh, GV; Onderdonk, AB; Parkinson, TM; Wingard, RE, 1983
)
0.27
"5-Aminosalicylic acid (5-ASA) is the active component of Salazopyrin and induces a prompt and excellent improvement, when administered as high dosage enema, in patients suffering from active ulcerative colitis."( A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis.
Bazzocchi, G; Bertoni, F; Brignola, C; Campieri, M; Labò, G; Lanfranchi, GA; Minguzzi, MR, 1984
)
1.23
"The study objective was to determine the minimum frequency of dosing for standard 4-g doses of p-aminosalicylic acid (PAS) granules."( Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
Berning, SE; Childs, JM; Huitt, GA; James, GT; Peloquin, CA; Singleton, MD, 1999
)
0.79
" CS is significantly removed by hemodialysis and should be dosed after hemodialysis."( The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.
Childs, JM; Fish, DN; Malone, RS; Peloquin, CA; Spiegel, DM, 1999
)
0.3
" The transfected cells were dosed with 4-aminosalicylic acid, sulfamethazine or solvent and the resulting luciferase activity was measured."( Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes.
Mitchell, KR; Warshawsky, D, 2003
)
0.58
" All patients with an unsatisfactory response to treatment yielded resistant cultures, showing that the isoniazid dosage was never too low to inhibit sensitive organisms."( THE EMERGENCE OF ISONIAZID-RESISTANT CULTURES IN PATIENTS WITH PULMONARY TUBERCULOSIS DURING TREATMENT WITH ISONIAZID ALONE OR ISONIAZID PLUS PAS.
DEVADATTA, S; KULKARNI, KG; MITCHISON, DA; NAIR, CN; NARAYANA, AS; RAMACHANDRAN, K; SELKON, JB, 1964
)
0.24
" Before mass domiciliary chemotherapy can be introduced, however, a question that has to be decided is what drug or drugs and what dosage and rhythm of administration will be most effective."( A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India.
, 1960
)
0.24
" The method was validated and proved to be useful for stability testing of the new dosage form."( Quantitative determination of p-aminosalicylic acid and its degradation product m-aminophenol in pellets by ion-pair high-performance liquid chromatography applying the monolithic Chromolith Speedrod RP-18e column.
Baeyens, WR; Debunne, A; García-Campaña, AM; Remon, JP; Van der Weken, G; Vander Heyden, Y; Vasbinder, E, 2004
)
0.61
" In 7 days the dosage was changed."( [Clinical pharmacokinetics of para-aminosalicylic acid tablets].
Miroshnichenko, II; Mokhireva, LV; Sokolova, GB, 2009
)
0.63
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" This study was designed to investigate the pharmacokinetics of PAS and its distribution in brain to help better design the dosing regimen for clinical trials."( Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese.
Hong, L; Jiang, W; Jiang, Y; Pan, H; Zeng, S; Zheng, W, 2011
)
0.64
" A 150 mg/kg PAS dosage given as one or two daily doses leads to plasma concentrations in children similar to those of adults receiving 4 g PAS twice daily."( Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation.
Diacon, AH; Donald, PR; Liwa, AC; Rosenkranz, B; Schaaf, HS; Seifart, HI, 2013
)
0.9
" This case study presents the development of a granular dosing spoon pediatric delivery system for para-aminosalicylic acid."( Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study.
Becerra, MC; Brigden, G; Furin, J; Lessem, E, 2013
)
0.6
" The present paper draws on these recent studies, synthesizes pharmacokinetic results from different population groups, and draws comparisons with in vitro data and the results of earlier pharmacokinetic studies in order to discuss the most appropriate dosing regimen for PAS-GR."( Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.
Brochart, H; Diacon, AH; Donald, PR; Kibleur, Y; Schaaf, HS, 2014
)
0.72
" A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index."( Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014
)
0.71
" All patients were included in a follow-up protocol developed by Lucane Pharma and the French Medicines Agency (ANSM) which recorded demographics, dosing characteristics, concomitant medications, adverse events, and outcome."( French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS(®) in MDR-TB patients.
Kibleur, Y; Veziris, N, 2014
)
0.4
" Four grams of GSR-PAS twice daily but not 8 g once daily ensured concentrations exceeding the MIC (1 mg/liter) throughout the dosing interval; PAS intolerance was not related to maximum PAS concentrations over the doses studied and was not more frequent after once-daily dosing."( N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.
de Kock, L; Diacon, AH; Donald, PR; Rosenkranz, B; Sy, SK; van der Merwe, L; Werely, CJ; Xia, H, 2015
)
0.64
"Therapeutic drug monitoring (TDM) of second-line antituberculosis drugs would allow for optimal individualized dosage adjustments and improve drug safety and therapeutic outcomes."( Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.
Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS, 2015
)
0.42
" In this Review, we assess published work regarding recommendations for PAS dosing in relation to efficacy and tolerance."( Para-aminosalicylic acid: the return of an old friend.
Diacon, AH; Donald, PR, 2015
)
0.93
" Individualized patient-based dosing of immunomodulators and biologic agents is now possible with therapeutic drug monitoring (TDM)."( Update on the Medical Management of Crohn's Disease.
Bruining, DH; Deepak, P, 2015
)
0.42
" In the future this technology could become a manufacturing technology for the elaboration of oral dosage forms, for industrial production or even for personalised dose."( Stereolithographic (SLA) 3D printing of oral modified-release dosage forms.
Basit, AW; Gaisford, S; Goyanes, A; Wang, J, 2016
)
0.43
" The current PASER dosing regimen is based on recommendations derived from older studies using a variety of different PAS formulations and relegate PAS to a role as an exclusively bacteriostatic agent."( The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.
Abulfathi, AA; Adams, K; Diacon, AH; Donald, PR; Reuter, H; Svensson, EM, 2020
)
0.85
" The objective of our study was to establish a representative population pharmacokinetics model for PASER and evaluate the probability of bactericidal and bacteriostatic target attainment with different dosing regimens."( Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Abulfathi, AA; Assawasuwannakit, P; Diacon, AH; Donald, PR; Reuter, H; Svensson, EM, 2020
)
0.81
" For the typical individual, the exposure remained above 1 mg/L for ≥ 98% of the dosing interval in all the evaluated PASER regimens."( Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Abulfathi, AA; Assawasuwannakit, P; Diacon, AH; Donald, PR; Reuter, H; Svensson, EM, 2020
)
0.81
" Among the mono-fluorinated analogs prepared, 5-fluoro-PAS, exhibited the best activity and an 11-fold decreased rate of inactivation by NAT-1 that translated to a 5-fold improved exposure as measured by area-under-the-curve (AUC) following oral dosing to CD-1 mice."( Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Aldrich, CC; Baughn, AD; Boshoff, HIM; Dartois, V; Hegde, PV; Howe, MD; Jia, Z; Pan, Y; Remache, B; Sharma, S; Zimmerman, MD, 2022
)
0.95
" Selected hit compounds were analyzed by dose-response and further probed with an intracellular macrophage assay."( A combination screening to identify enhancers of para-aminosalicylic acid against Mycobacterium tuberculosis.
Brodin, P; Choi, I; de Almeida Falcão, VC; Delorme, V; Heo, J; Jang, J; Kim, K; Koh, D; Kwon, D; Lee, H; Shum, D; Woo, M; Wood, C, 2022
)
0.97
" The optimal dosing of PAS in children is uncertain, specifically for delayed-release granule preparations, which are the most used."( Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
Chirehwa, M; Denti, P; Donald, PR; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Mao, J; McIlleron, H; Norman, J; Schaaf, HS; van der Laan, LE; Wiesner, L; Winckler, JL, 2022
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antitubercular agentA substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminobenzoic acid
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency3.54810.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency0.39810.00527.809829.0929AID588855
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
microphthalmia-associated transcription factor isoform 9Homo sapiens (human)IC50 (µMol)2.83410.00481.37104.9290AID1259371; AID1259373; AID1259375
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)130.00000.00582.14107.9000AID349140
Carbonic anhydrase 1Homo sapiens (human)Ki240.00000.00001.372610.0000AID349142
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)750.00000.00021.10608.3000AID349141
Carbonic anhydrase 2Homo sapiens (human)Ki1,230.00000.00000.72369.9200AID349145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)Kd1,200.00006.08006.08006.0800AID165006; AID165009; AID165322; AID1674199
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (324)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID415828Antiinflammatory activity against TNBS-induced Wistar rat colitis model assessed as decrease in ratio of colon to body weight treated rectally 3 days after TNBS induction for 8 days measured after 24 hrs of last treatment2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID557248Antimicrobial activity against Mycobacterium tuberculosis harboring 153Y to Stop mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID619383Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 272942011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1676588Binding affinity to Zinc ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1397963Inhibition of mouse recombinant glycolate oxidase expressed in Escherichia coli at 25 uM using glycolate as substrate after 1 min by sulfonated DCIP dye-based assay relative to control2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.
AID1272106Antiulcerative colitis activity in TNBS-induced Sprague-Dawley rat colitis model assessed as decrease in severity of inflammation at 115 mg/kg qd for 6 consecutive days measured on 7th day2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID1295091Tuberculostatic activity against multi-drug resistant Mycobacterium tuberculosis isolates assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1879683AUC in CD-1 mouse plasma assessed as para-aminosalicylic acid AUC at 25 mg/kg, po administered as single dose and measured up to 24 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1339421Antimycobacterial activity against Mycobacterium kansasii isolate 235/80 after 21 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID619388Antimycobacterial activity against Mycobacterium kansasii CNTC My 235/80 after 14 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID557257Antimicrobial activity against Mycobacterium tuberculosis harboring 259A to P mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID1511427Antibacterial activity against Burkholderia thailandensis at 0.5 mM by Kirby Bauer disk diffusion method2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
AID619391Antimycobacterial activity against Mycobacterium kansasii CNTC 6509/96 after 14 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID1375997Inhibition of QCR6 A317T mutant in Mycobacterium tuberculosis H37Rv harboring cyd deletion mutant assessed as reduction in bacterial growth relative to wild-type QCR62016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID557263Antimicrobial activity against Mycobacterium tuberculosis harboring 183L to V mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID445285Antibacterial activity against Mycobacterium bovis BCG str. Tokyo 172 by broth dilution method2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis.
AID1146780Hydrolytic dissociation constant, pKa of the compound in aqueous solution at 50 degC1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID1146779Dissociation constant, pKa of the compound by spectrophotometric analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID1063979Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 21 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID445290Antibacterial activity against Escherichia coli by broth dilution method2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1608990Antimycobacterial activity against Mycobacterium avium 330/88 after 14 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID575507Antimicrobial activity against Mycobacterium tuberculosis LAM 8885/05 harboring thyA Thr202Ala single nucleotide polymorphism grown in 7H9 broth assessed as decrease in bacterial growth at 0.125 to 2 ug/ml by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID1676602Binding affinity to ferric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1511433Antibacterial activity against Corynebacterium xerosis at 0.5 mM by Kirby Bauer disk diffusion method2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
AID1676596Binding affinity to Ferric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID545236Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID557251Antimicrobial activity against Mycobacterium tuberculosis harboring 264Stop to R mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1511429Antibacterial activity against Bacillus cereus at 0.5 mM by Kirby Bauer disk diffusion method2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
AID619382Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis A8 241 after 28 days by colony forming unit determination2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID1375993Inhibition of QCR2 M342T mutant in Mycobacterium tuberculosis H37Rv harboring cyd deletion mutant assessed as reduction in bacterial growth relative to wild-type QCR22016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID1272091Drug level in Sprague-Dawley rat stomach homogenate treated with sodium 4-amino-2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yloxy)benzoate at pH 4.5 by HPLC analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1191498Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID1608996Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1676589Binding affinity to Nickel cation assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1146784Inhibition of Escherichia coli dihydropteroic acid synthesizing system-mediated folate production at 50 to 250 umol/l1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID1063978Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID557252Antimicrobial activity against Mycobacterium tuberculosis harboring 127R to L mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID1879689Antimycobacterial activity against drug susceptible Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth measured after 2 weeks by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1676590Binding affinity to Nickel cation assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1063980Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 14 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID1191496Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID557259Antimicrobial activity against Mycobacterium tuberculosis harboring 263V to I mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1272105Drug level in colitis Sprague-Dawley rat model colon treated with sodium 4-amino-2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yloxy)benzoate at pH 7.4 after 12 hrs by HPLC analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID619381Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by colony forming unit determination2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID445286Antibacterial activity against Mycobacterium avium 724S by broth dilution method2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis.
AID285161Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1146777Lipophilic-hydrophilic balance, Rm of the compound by TLC analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID575509Antimicrobial activity against Mycobacterium tuberculosis Beijing 1934/03 harboring thyA Thr202Ala single nucleotide polymorphism grown in 7H9 broth assessed as decrease in bacterial growth at 0.125 to 2 ug/ml by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID1063984Antimycobacterial activity against isoniazid, rifampicin, ethambutol and ofloxacin-resistant Mycobacterium avium My 330/88 after 14 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID1146787Activity of dihydropteroate synthase (unknown origin) assessed as rate of compound incorporation on dihydropteroic acid analogues incubated for 5 hrs under argon atmosphere by fluorescence assay1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID1191521Cytostatic activity against human HepG2 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1511435Antibacterial activity against Micrococcus luteus at 0.5 mM by Kirby Bauer disk diffusion method2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
AID1608998Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1676595Binding affinity to Ferric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1375992Inhibition of QCR1 A317V mutant in Mycobacterium tuberculosis H37Rv harboring cyd deletion mutant assessed as reduction in bacterial growth relative to wild-type QCR12016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID1879688Substrate activity at human NAT-1 F125S mutant assessed as ratio of Kcat to Km using PNPA as substrate by Michaelis-Menten based analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID545233Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID619386Antimycobacterial activity against Mycobacterium avium CNTC 330/88 after 21 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID165006Dissociation constant against protein tyrosine phosphatase PTB1B receptor was determined2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor.
AID1375989Antimycobacterial activity against Mycobacterium tuberculosis H37Rv measured after 2 weeks2016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID557261Antimicrobial activity against Mycobacterium tuberculosis harboring 91G to E mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID1609016Selectivity index, ratio of IC50 for human HepG2 cells to MIC for antimycobacterial activity against Mycobacterium kansasii 235/802019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID417725Antiinflammatory activity against TNBS-induced po dosed Wistar rat colitis model assessed as inhibition of MPO activity in neutrophils per 100 mg of tissue2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID545235Antimycobacterial activity against multidrug-resistant Mycobacterium avium 330/88 after 21 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID355266Antitubercular activity against Mycobacterium tuberculosis H37Rv after 21 days by broth microdilution method1997Journal of natural products, Dec, Volume: 60, Issue:12
Norditerpenoids and diterpenoids from Salvia multicaulis with antituberculous activity.
AID1272103Drug level in colitis Sprague-Dawley rat model cecum treated with sodium 4-amino-2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yloxy)benzoate at pH 7.4 after 12 hrs by HPLC analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID1339423Antimycobacterial activity against Mycobacterium kansasii isolate 6509/96 after 14 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1676594Binding affinity to gallium ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1339424Antimycobacterial activity against Mycobacterium kansasii isolate 6509/96 after 21 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1511432Antibacterial activity against Klebsiella pneumoniae at 0.5 mM by Kirby Bauer disk diffusion method2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
AID1609013Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after overnight incubation by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1653492Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in CF-1 mouse assessed as change in survival time at 4 mg/kg administrated daily for 14 days with food relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1608994Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1375998Inhibition of QCR7 S182T mutant in Mycobacterium tuberculosis H37Rv harboring cyd deletion mutant assessed as reduction in bacterial growth relative to wild-type QCR72016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID1191490Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID557264Antimicrobial activity against Mycobacterium tuberculosis harboring 191Q to R mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID557262Antimicrobial activity against Mycobacterium tuberculosis harboring 91G to R mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1191492Antimycobacterial activity against INH,RIF,OFX,EMB-resistant Mycobacterium avium 330/88 after 21 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID1375988Antimycobacterial activity against Mycobacterium tuberculosis H37Rv measured after 1 week2016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID575504Antimicrobial activity against Mycobacterium tuberculosis Beijing 1934/03 harboring thyA Thr202Ala single nucleotide polymorphism grown in Lowenstein-Jensen medium2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID545238Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID1180438Antimycobacterial activity against Mycobacterium kansasii 235/80 assessed as complete growth inhibition after 7 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1180437Antimycobacterial activity against Isoniazid, rifampicin, ofloxacin and ethambutol-resistant Mycobacterium avium 330/88 assessed as complete growth inhibition after 21 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1676601Binding affinity to Zinc ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1879684Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth measured after 10 days by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID575501Antimicrobial activity against Mycobacterium tuberculosis Haarlem 9532/03 harboring thyA Thr202Ala single nucleotide polymorphism grown in Lowenstein-Jensen medium2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID349140Inhibition of human carbonic anhydrase 1 esterase activity by spectrophotometry2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1180455Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID417722Antiinflammatory activity against TNBS-induced Wistar rat colitis model assessed as decrease in severity of inflammation treated rectally 3 days after TNBS induction measured on day 72009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID349141Inhibition of human carbonic anhydrase 2 esterase activity by spectrophotometry2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID445210Antituberculosis activity against Mycobacterium tuberculosis H37Rv by broth dilution method2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis.
AID1609014Cytostatic activity against human HepG2 cells preincubated for overnight in serum free medium followed by compound wash out and further incubated for 72 hrs in presence of serum by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1375987Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 2 weeks by microplate alamar blue assay2016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID1609015Selectivity index, ratio of IC50 for human HepG2 cells to MIC for antimycobacterial activity against Mycobacterium tuberculosis H37Rv2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1180441Antimycobacterial activity against clinical isolate Mycobacterium kansasii 6509/96 assessed as complete growth inhibition after 7 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1676591Binding affinity to Nickel cation assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1272101Drug level in colitis Sprague-Dawley rat model small intestine homogenate treated with sodium 4-amino-2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yloxy)benzoate at pH 6.8 by HPLC analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID1053268Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1295093Toxicity in healthy mouse administered as single peroral dose measured after 14 days2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1180444Inhibition of Mycobacterium tuberculosis H37Rv isocitrate lyase assessed as glyoxylate phenyl hydrazone formation at 10 uM2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1339419Antimycobacterial activity against Mycobacterium kansasii isolate 235/80 after 7 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1511431Antibacterial activity against Mycobacterium smegmatis at 0.5 mM by Kirby Bauer disk diffusion method2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
AID1272095Drug level in Sprague-Dawley rat cecum treated with sodium 4-amino-2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yloxy)benzoate at pH 7.4 after 12 hrs by HPLC analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID436610Antitubercular activity against Mycobacterium tuberculosis Erdman by broth dilution method2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1295092Antimicrobial activity against Mycobacterium tuberculosis2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1676600Binding affinity to zinc ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1272097Drug level in Sprague-Dawley rat colon treated with sodium 4-amino-2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yloxy)benzoate at pH 7.4 after 12 hrs by HPLC analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID1608999Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1272124Antiulcerative colitis activity in TNBS-induced Sprague-Dawley rat colitis model assessed as myeloperoxidase activity at 115 mg/kg, qd for 6 consecutive days by spectrophotometry (Rvb = 1.44 +/- 0.041 U/g)2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID1608993Antimycobacterial activity against Mycobacterium avium 330/88 after 21 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID619384Selectivity index, ratio of IC50 for human HepG2 cells to MIC for multidrug-resistant Mycobacterium tuberculosis A8 2412011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID545240Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID575502Antimicrobial activity against Mycobacterium tuberculosis LAM 7968/03 harboring thyA Thr202Ala single nucleotide polymorphism grown in Lowenstein-Jensen medium2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID557260Antimicrobial activity against Mycobacterium tuberculosis harboring 15G to R mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID557258Antimicrobial activity against Mycobacterium tuberculosis harboring 261V to G mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1676592Binding affinity to Gallium ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1339416Antimycobacterial activity against Mycobacterium tuberculosis H37Rv My 331/88 after 21 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID165322Dissociation constant for Protein-tyrosine phosphatase 1B2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Fragment-based drug discovery.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID619390Antimycobacterial activity against Mycobacterium kansasii CNTC 6509/96 after 7 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID1180439Antimycobacterial activity against Mycobacterium kansasii 235/80 assessed as complete growth inhibition after 14 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID557245Antimicrobial activity against Mycobacterium tuberculosis harboring 83W to Stop mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID557255Antimicrobial activity against Mycobacterium tuberculosis harboring 172L to P mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID575503Antimicrobial activity against Mycobacterium tuberculosis LAM 8885/05 harboring thyA Thr202Ala single nucleotide polymorphism grown in Lowenstein-Jensen medium2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID1063976Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID1180440Antimycobacterial activity against Mycobacterium kansasii 235/80 assessed as complete growth inhibition after 21 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1191489Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID285160Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1339417Antimycobacterial activity against Mycobacterium avium My 330/80 after 14 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1879693Antimycobacterial activity against PAS resistant Mycobacterium tuberculosis H37Rv harboring S150G mutant assessed as inhibition of bacterial growth measured after 2 weeks by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID445287Antibacterial activity against Mycobacterium avium SmO by broth dilution method2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis.
AID1191525Selectivity index, ratio of IC50 for human HepG2 cells to MIC for atypical mycobacteria2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID417734Partition coefficient, log p in n-octanol/phosphate buffer at pH 7.42009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID1295088Tuberculostatic activity against Mycobacterium tuberculosis H37Rv assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1653486Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in CF-1 mouse assessed as change in survival time at 2 mg/kg administrated daily for 14 days with food relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID445288Antibacterial activity against Mycobacterium smegmatis by broth dilution method2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID557265Antimicrobial activity against Mycobacterium tuberculosis harboring 202T to A mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID619389Antimycobacterial activity against Mycobacterium kansasii CNTC My 235/80 after 21 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID1295090Tuberculostatic activity against Mycobacterium terrae assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1879690Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth measured after 2 weeks by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1180434Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 assessed as complete growth inhibition after 14 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1191493Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1879687Substrate activity at human NAT-1 F125S mutant assessed as Kcat using PNPA as substrate by Michaelis-Menten based analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID349145Inhibition of human carbonic anhydrase 2 esterase activity by non-competitive Lineweaver-Burke plot2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID1180442Antimycobacterial activity against clinical isolate Mycobacterium kansasii 6509/96 assessed as complete growth inhibition after 14 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1879692Antimycobacterial activity against PAS resistant Mycobacterium tuberculosis H37Rv harboring E153A mutant assessed as inhibition of bacterial growth measured after 2 weeks by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1375996Inhibition of QCR5 M342I mutant in Mycobacterium tuberculosis H37Rv harboring cyd deletion mutant assessed as reduction in bacterial growth relative to wild-type QCR52016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1879694Antimycobacterial activity against PAS resistant Mycobacterium tuberculosis H37Rv harboring R49W mutant assessed as inhibition of bacterial growth measured after 2 weeks by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1063977Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID1295089Tuberculostatic activity against Mycobacterium avium assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.
AID1339422Antimycobacterial activity against Mycobacterium kansasii isolate 6509/96 after 7 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1375995Inhibition of QCR4 A396T mutant in Mycobacterium tuberculosis H37Rv harboring cyd deletion mutant assessed as reduction in bacterial growth relative to wild-type QCR42016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID1879685Ratio of compound AUC to para-aminosalicylic acid AUC in CD-1 mouse2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1180436Antimycobacterial activity against Isoniazid, rifampicin, ofloxacin and ethambutol-resistant Mycobacterium avium 330/88 assessed as complete growth inhibition after 14 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1511430Antibacterial activity against Escherichia coli at 0.5 mM by Kirby Bauer disk diffusion method2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
AID557246Antimicrobial activity against Mycobacterium tuberculosis harboring 11Q to Stop mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID545234Antimycobacterial activity against multidrug-resistant Mycobacterium avium 330/88 after 14 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID1653495Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in CF-1 mouse assessed as change in survival time at 6 mg/kg administrated daily for 14 days with food relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID557249Antimicrobial activity against Mycobacterium tuberculosis harboring 164Y to Stop mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID436230Gastrointestinal toxicity in Wistar rat assessed as ulcer index at 1154.3 mg/kg, po by Rainsford's cold stress method2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID1063985Antimycobacterial activity against Mycobacterium tuberculosis H37Rv My 331/88 after 21 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID557254Antimicrobial activity against Mycobacterium tuberculosis harboring 146C to R mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID1676593Binding affinity to Gallium ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1674199Binding affinity to N-terminal GST-fused human PTP1B (1 to 288 residues) expressed in Escherichia coli BL21(DE3) by HSQC NMR analysis2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Fragment Linking Strategies for Structure-Based Drug Design.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID417721Antiinflammatory activity against TNBS-induced Wistar rat colitis model assessed as decrease in severity of inflammation treated po 3 days after TNBS induction measured on day 72009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID1272088Partition coefficient, log P of the compound at pH 7.4 by shake flask method2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID575500Antimicrobial activity against Mycobacterium tuberculosis H37Rv 9679/00 harboring thyA Thr202Ala single nucleotide polymorphism grown in 7H9 broth assessed as decrease in bacterial growth at 0.125 to 2 ug/ml by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID1146778Antimicrobial activity against Escherichia coli assessed as growth inhibition after 24 hrs by turbidimetric analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1191497Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID1609017Selectivity index, ratio of IC50 for human HepG2 cells to MIC for antimycobacterial activity against Mycobacterium avium 330/882019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1191495Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID1609011Inhibition of recombinant Mycobacterium tuberculosis H37Rv ICL1 expressed in Escherichia coli BL21 (DE3) cells at 10 uM using (+)-potassium Ds-threo-isocitrate as substrate by glyoxylate phenyl hydrazone formation assay relative to control2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1608997Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1180443Antimycobacterial activity against clinical isolate Mycobacterium kansasii 6509/96 assessed as complete growth inhibition after 21 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1191494Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1272099Drug level in colitis Sprague-Dawley rat model stomach homogenate treated with sodium 4-amino-2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yloxy)benzoate at pH 4.5 by HPLC analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID1676599Binding affinity to cupric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID557256Antimicrobial activity against Mycobacterium tuberculosis harboring 182A to P mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID1272093Drug level in Sprague-Dawley rat small intestine homogenate treated with sodium 4-amino-2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yloxy)benzoate at pH 6.8 by HPLC analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1272113Antiulcerative colitis activity in TNBS-induced Sprague-Dawley rat colitis model assessed as effect on TNBS-induced mucosal abscess at 115 mg/kg qd for 6 consecutive days by hematoxylin and eosin staining based light microscopic analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID445289Antibacterial activity against Staphylococcus aureus by broth dilution method2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis.
AID285162Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID557250Antimicrobial activity against Mycobacterium tuberculosis harboring 251Y to Stop mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID1180456Selectivity index, ratio of IC50 for human HepG2 cells to MIC for atypical mycobacteria2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1180460Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis H37Rv2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1146775Binding affinity to human serum albumin at 100 umol/l by equilibrium dialysis technique1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1339415Antimycobacterial activity against Mycobacterium tuberculosis H37Rv My 331/88 after 14 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1063981Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter assay2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1608995Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1676598Binding affinity to cupric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1191491Antimycobacterial activity against INH,RIF,OFX,EMB-resistant Mycobacterium avium 330/88 after 14 days by microdilution method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID1608991Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID417729Ulcerogenic effect in rat colon assessed as ulcer index at 1154.30 mg/kg by Rainsford's cold stress method2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
AID619385Antimycobacterial activity against Mycobacterium avium CNTC 330/88 after 14 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID1608992Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days2019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1879678AUC in CD-1 mouse plasma assessed as para-aminosalicylic acid AUC at 10 mg/kg, po administered as single dose and measured up to 5 hrs by HPLC-MS/MS analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID545239Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID285159Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1609018Selectivity index, ratio of IC50 for human HepG2 cells to MIC for antimycobacterial activity against Mycobacterium kansasii 6509/962019European journal of medicinal chemistry, Nov-01, Volume: 181Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
AID1511428Antibacterial activity against Pseudomonas aeruginosa at 0.5 mM by Kirby Bauer disk diffusion method2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
AID1339418Antimycobacterial activity against Mycobacterium avium My 330/80 after 21 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID575506Antimicrobial activity against Mycobacterium tuberculosis LAM 7968/03 harboring thyA Thr202Ala single nucleotide polymorphism grown in 7H9 broth assessed as decrease in bacterial growth at 0.125 to 2 ug/ml by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID1676597Binding affinity to cupric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1272089Aqueous solubility of the compound2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID349142Inhibition of human carbonic anhydrase 1 esterase activity by noncompetitive Lineweaver-Burke plot2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID545241Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID165009Protein-tyrosine phosphatase 1B (PTP 1B) site 2 Ligands were identified using [13C]-labeled protein and their Dissociation Constants were determined2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands.
AID1375990Antimycobacterial activity against Mycobacterium tuberculosis H37Rv harboring cyd deletion mutant measured after 2 weeks by microplate alamar blue assay2016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID1511434Antibacterial activity against Corynebacterium pseudodiphtheriticum at 0.5 mM by Kirby Bauer disk diffusion method2019Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20
Antibacterial activity of 2-amino-4-hydroxypyrimidine-5-carboxylates and binding to Burkholderia pseudomallei 2-C-methyl-d-erythritol-2,4-cyclodiphosphate synthase.
AID575508Antimicrobial activity against Mycobacterium tuberculosis Haarlem 9532/03 harboring thyA Thr202Ala single nucleotide polymorphism grown in 7H9 broth assessed as decrease in bacterial growth at 0.125 to 2 ug/ml by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID1063982Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 7 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID1272114Antiulcerative colitis activity in TNBS-induced Sprague-Dawley rat colitis model assessed as effect on TNBS-induced inflammatory infiltrate at 115 mg/kg qd for 6 consecutive days by hematoxylin and eosin staining based light microscopic analysis2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID619392Antimycobacterial activity against Mycobacterium kansasii CNTC 6509/96 after 21 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID1191522Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1375994Inhibition of QCR3 W312G mutant in Mycobacterium tuberculosis H37Rv harboring cyd deletion mutant assessed as reduction in bacterial growth relative to wild-type QCR32016MedChemComm, Nov-01, Volume: 7, Issue:11
SAR and identification of 2-(quinolin-4-yloxy)acetamides as
AID1879686Substrate activity at recombinant human NAT-1 F125S mutant assessed as Km using PNPA as substrate by Michaelis-Menten based analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID557253Antimicrobial activity against Mycobacterium tuberculosis harboring 143L to P mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID1339420Antimycobacterial activity against Mycobacterium kansasii isolate 235/80 after 14 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1180435Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 assessed as complete growth inhibition after 21 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID575505Antimicrobial activity against Mycobacterium tuberculosis H37Rv 9679/00 harboring thyA Thr202Ala single nucleotide polymorphism grown in Lowenstein-Jensen medium2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1191523Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
AID557247Antimicrobial activity against Mycobacterium tuberculosis harboring 118L to Stop mutation in thymidylate synthase A by agar dilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
AID545237Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1653494Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in CF-1 mouse assessed as change in survival time at 850 mg/kg administrated daily for 14 days with food relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1063983Antimycobacterial activity against isoniazid, rifampicin, ethambutol and ofloxacin-resistant Mycobacterium avium My 330/88 after 21 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID1063986Antimycobacterial activity against Mycobacterium tuberculosis H37Rv My 331/88 after 14 days2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
AID251752Antimycobacterial activity of compound against Mycobacterium tuberculosis H37Rv at 8 ug/mL2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Antituberculous activity of some aryl semicarbazone derivatives.
AID545232Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days by micromethod2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
AID1854055Anti-mycobacterial activity against Mycobacterium tuberculosis H37Rv incubated for 5 days by alamar blue assay2022RSC medicinal chemistry, Mar-23, Volume: 13, Issue:3
Design, synthesis and anti-mycobacterial evaluation of imidazo[1,2-
AID1351272Ratio of MIC90 for Mycobacterium bovis BCG over-expressing DHFR to MIC90 for Mycobacterium bovis BCG2018European journal of medicinal chemistry, Jan-20, Volume: 1441,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity.
AID619387Antimycobacterial activity against Mycobacterium kansasii CNTC My 235/80 after 7 days2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
New fluorine-containing hydrazones active against MDR-tuberculosis.
AID1879691Antimycobacterial activity against extensively drug resistant Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth measured after 2 weeks by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,503)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903071 (87.67)18.7374
1990's91 (2.60)18.2507
2000's80 (2.28)29.6817
2010's169 (4.82)24.3611
2020's92 (2.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.09 (24.57)
Research Supply Index8.30 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index110.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (63.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials55 (1.39%)5.53%
Reviews79 (2.00%)6.00%
Case Studies60 (1.52%)4.05%
Observational2 (0.05%)0.25%
Other3,762 (95.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (21)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-blind, Placebo-controlled Study to Evaluated the Efficacy of Combining Curcumin+5ASA Medication Versus 5ASA Medication Alone on Active Mild to Moderate Ulcerative Colitis Patients [NCT01320436]Phase 350 participants (Actual)Interventional2011-07-31Completed
Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis [NCT03625739]800 participants (Anticipated)Observational [Patient Registry]2018-07-01Recruiting
A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers [NCT02128308]Phase 116 participants (Actual)Interventional2013-11-30Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]1,578 participants (Actual)Observational2003-06-09Completed
Mesalamine to Reduce T Cell Activation in HIV Infection [NCT01090102]Phase 433 participants (Actual)Interventional2010-06-30Completed
A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8g/Day) 400 mg Delayed-release Tablets Given Twice Daily for 26 Weeks to Children and Adolescents for the Maintenance of Remission of Ulcerative Coliti [NCT01004185]Phase 339 participants (Actual)Interventional2009-10-31Terminated(stopped due to Pediatric enrollment very slow.)
"Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari in Vivo Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)" [NCT02077777]Phase 221 participants (Actual)Interventional2012-10-31Completed
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome - MesaCAPP [NCT03070574]Phase 28 participants (Actual)Interventional2017-11-24Terminated(stopped due to Due to poor patient recruitment and insufficient financing.)
A Phase I Double-blind, Randomized, Comparator-controlled Study of the Safety and Tolerability of N-acetylcysteine Plus Mesalamine Enema in Subjects With Left-sided Ulcerative Colitis [NCT01020708]Phase 19 participants (Anticipated)Interventional2009-11-30Completed
The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis [NCT02683733]Phase 350 participants (Anticipated)Interventional2016-02-29Recruiting
A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease [NCT00495521]Phase 22 participants (Actual)Interventional2007-06-30Terminated(stopped due to Efforts at recruitment have halted as recruitment was poor)
Impact of Co-Receptor and HIV Viral Burden on Gut Mucosa [NCT00069498]Phase 114 participants Interventional1999-10-31Completed
Efficacy and Safety of Fecal Microbiota Transplantation for Ulcerative Colitis [NCT03804931]Phase 2/Phase 3120 participants (Anticipated)Interventional2019-01-20Recruiting
Conventional Step-Up Versus Infliximab Monotherapy in Patients With Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study [NCT00984568]Phase 328 participants (Actual)Interventional2009-11-30Terminated(stopped due to Due to slow recruitment the study was stopped prematurely.)
A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease [NCT00417690]Phase 254 participants (Anticipated)Interventional2007-01-31Terminated(stopped due to Efforts at recruitment have halted as recruitment was poor.)
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in [NCT00000796]525 participants InterventionalCompleted
[NCT00004810]Phase 230 participants Interventional1996-06-30Completed
[NCT00004423]80 participants Interventional1995-12-31Completed
A Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of A Contezolid, Delamanid and Bedaquiline-Containing Short Regimen For The Treatment Of Rifampicin-Resistant Pulmonary Tuberculosis [NCT06081361]Phase 3186 participants (Anticipated)Interventional2023-11-01Not yet recruiting
A Retrospective Study to Assess 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea [NCT04499495]11,385 participants (Actual)Observational2021-10-25Completed
An Open-label, Randomized, Crossover Study to Evaluate the Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects [NCT03070405]Phase 120 participants (Anticipated)Interventional2016-10-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00042289 (26) [back to overview]Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00495521 (2) [back to overview]Rate of Remission
NCT00495521 (2) [back to overview]Reduction in the Modified Crohn's Disease Activity Index (mCDAI) Score of >70 Points by 4 Weeks Compared With Baseline
NCT00984568 (2) [back to overview]Number of Participants Achieving Treatment Response
NCT00984568 (2) [back to overview]Number of Participants With Response at Week 4 and Steroid-Free Remission at Week 50
NCT01004185 (2) [back to overview]Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population
NCT01004185 (2) [back to overview]Treatment Success PUCAI Amended Endpoint (5 Point Scale Abdominal Pain), mITT
NCT01090102 (2) [back to overview]Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells After Treatment Crossover
NCT01090102 (2) [back to overview]Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. Half-life is defined as 0.693/k, where k, the elimination rate constant, is the slope of the decline in concentrations. (NCT00042289)
Timeframe: Infant plasma samples at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

Interventionhour (Median)
DTG 50mg q.d.32.8
EVG/COBI 150/150mg q.d.7.6
DRV/COBI 800/150 mg q.d.NA
EFV 600 mg q.d. (Outside THA)65.6

[back to top]

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.0.15
DTG 50mg q.d.1.25
EVG/COBI 150/150mg q.d.0.91
DRV/COBI 800/150 mg q.d.0.07
ATV/COBI 300/150 mg q.d.0.07
TFV 300mg q.d.0.88

[back to top]

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. For arms with zero overall participants analyzed, samples were below the limit of quantification and ratios could not be calculated. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
TAF 10mg q.d. w/COBI0.97
EFV 600 mg q.d. (Outside THA)0.67
EFV 600mg q.d.0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.0.2
RAL 400mg b.i.d.1.5
ETR 200mg b.i.d.0.52
MVC 150 or 300mg b.i.d.0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.12
RPV 25mg q.d.0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.0.18

[back to top]

Plasma Concentration for Contraceptives

Serum concentrations of the contraceptives. Note that no historical controls were provided by team pharmacologists and thus no comparisons were done for contraceptive concentrations in women using hormonal contraceptives and selected ARV drugs as compared to historical controls not using those ARV drugs. (NCT00042289)
Timeframe: Measured at 6-7 weeks after contraceptive initiation postpartum

Interventionpg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG604
LPV/RTV 400/100 b.i.d. With ENG428
EFV 600mg q.d. With ENG125

[back to top]

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.

Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG115.97100.20

[back to top]

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.

,
Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG53.9655.25
EFV 600mg q.d. With ENG53.6456.65

[back to top]

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,
InterventionParticipants (Count of Participants)
3rd TrimesterPostpartum
EFV 600mg q.d.2021
MVC 150 or 300mg b.i.d.87

[back to top]

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,,,,,,,,,,,,,,,,,,,,,,
InterventionParticipants (Count of Participants)
2nd Trimester3rd TrimesterPostpartum
ATV/RTV Arm 1: 300/100mg q.d.11212
DRV/COBI 800/150 mg q.d.3414
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.71622
DRV/RTV 600/100mg b.i.d.71922
DRV/RTV 800/100mg q.d.91922
DTG 50mg q.d.92023
EFV 600 mg q.d. (Outside THA)123334
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.82927
ETR 200mg b.i.d.5137
EVG/COBI 150/150mg q.d.81018
FPV/RTV 700/100mg b.i.d.82622
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)101926
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.93027
ATV/COBI 300/150 mg q.d.125
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA1514
RAL 400mg b.i.d.113330
RPV 25mg q.d.142625
TAF 10mg q.d. w/COBI152322
TAF 25mg q.d.132324
TAF 25mg q.d. w/COBI or RTV Boosting102418
TFV 300mg q.d.22727
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.11112
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.72332

[back to top]

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. (NCT00042289)
Timeframe: Blood samples were collected at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

,,,
Interventionmcg/mL (Median)
2-10 hours after birth18-28 hours after birth36-72 hours after birth5-9 days after birth
DRV/COBI 800/150 mg q.d.0.351.431.871.72
DTG 50mg q.d.1.731.531.000.06
EFV 600 mg q.d. (Outside THA)1.11.00.90.4
EVG/COBI 150/150mg q.d.0.1320.0320.0050.005

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

Interventionng*hour/mL (Geometric Mean)
2nd Trimester3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.NA27173645

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.55.151.879.6
DRV/RTV 600/100mg b.i.d.45.845.961.7
FPV/RTV 700/100mg b.i.d.43.5032.1551.60
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA34.233.5

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.4.58.35.3
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)14.916.127.1
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.7296133
RAL 400mg b.i.d.6.65.411.6

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24 (area under the curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

,,,,,,,,,,,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.25.3318.8536.20
ATV/RTV Arm 1: 300/100mg q.d.88.241.957.9
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.30.645.748.8
DRV/COBI 800/150 mg q.d.50.0042.0595.55
DRV/RTV 800/100mg q.d.64.663.5103.9
DTG 50mg q.d.47.649.265.0
EFV 600 mg q.d. (Outside THA)47.3060.0262.70
EVG/COBI 150/150mg q.d.15.314.021.0
TAF 10mg q.d. w/COBI0.1970.2060.216
TAF 25mg q.d.0.1710.2120.271
TAF 25mg q.d. w/COBI or RTV Boosting0.1810.2570.283
TFV 300mg q.d.1.92.43.0
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.14.528.839.6
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.26.237.758.7

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.55.458.3

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.1.9691.6692.387

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.5.445.10

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.2.822.203.90
ATV/RTV Arm 1: 300/100mg q.d.NA3.64.1
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.3.114.514.52
DRV/COBI 800/150 mg q.d.4.593.677.04
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.6.226.558.96
DRV/RTV 600/100mg b.i.d.5.645.537.78
DRV/RTV 800/100mg q.d.6.775.788.11
DTG 50mg q.d.3.623.544.85
EFV 600 mg q.d. (Outside THA)3.875.134.41
FPV/RTV 700/100mg b.i.d.5.615.126.75
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)3.893.625.37
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA5.15.0
TFV 300mg q.d.0.2500.2450.298
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.1.22.54.1
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.2.733.565.43

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.701.010.63
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.8.410.714.6
RAL 400mg b.i.d.2.2501.7703.035
RPV 25mg q.d.0.1450.1340.134

[back to top]

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionng/mL (Median)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.448647

[back to top]

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionng/mL (Median)
2nd Trimester3rd TrimesterPostpartum
EVG/COBI 150/150mg q.d.1447.11432.81713.1
TAF 10mg q.d. w/COBI80.491.298.2
TAF 25mg q.d.69.796133
TAF 25mg q.d. w/COBI or RTV Boosting87.8107141

[back to top]

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

Interventionng/mL (Geometric Mean)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.108128

[back to top]

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.2.842.524.51
DRV/RTV 600/100mg b.i.d.2.122.222.51
FPV/RTV 700/100mg b.i.d.2.121.642.87
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA0.470.52

[back to top]

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.360.480.38
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.130.130.28
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.3.75.17.2
RAL 400mg b.i.d.0.06210.0640.0797

[back to top]

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

"Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose.~For the TAF 25 mg q.d., 10 mg q.d. w/COBI, and 25 mg q.d. w/COBI or RTV boosting arms, samples were all below the limit of quantification and statistical analyses were not conducted." (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.0.210.210.61
ATV/RTV Arm 1: 300/100mg q.d.2.00.71.2
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.490.710.90
DRV/COBI 800/150 mg q.d.0.330.271.43
DRV/RTV 800/100mg q.d.0.991.172.78
DTG 50mg q.d.0.730.931.28
EFV 600 mg q.d. (Outside THA)1.491.481.94
EVG/COBI 150/150mg q.d.0.02580.04870.3771
TAF 10mg q.d. w/COBI0.001950.001950.00195
TAF 25mg q.d.0.001950.001950.00195
TAF 25mg q.d. w/COBI or RTV Boosting0.001950.001950.00195
TFV 300mg q.d.0.0390.0540.061
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.0.30.50.8
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.440.571.26

[back to top]

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.1.602.05

[back to top]

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.0.0630.0560.081

[back to top]

Rate of Remission

Rate of remission was defined by a decrease in modified Crohn's Disease Activity Index (mCDAI) > 100 points and total mCDAI < 150 by 4 weeks (NCT00495521)
Timeframe: 4 weeks

InterventionParticipants (Count of Participants)
Active1
Placebo1

[back to top]

Reduction in the Modified Crohn's Disease Activity Index (mCDAI) Score of >70 Points by 4 Weeks Compared With Baseline

Reduction in the Modified Crohn's Disease Activity Index (mCDAI) score of >70 points by 4 weeks after randomization compared with baseline (NCT00495521)
Timeframe: 4 weeks

Interventionparticipants (Number)
Active1
Placebo1

[back to top]

Number of Participants Achieving Treatment Response

"Response was defined as a minimum decrease from baseline in total Mayo score of 3 points and 30% up to and including 4 weeks after the start of treatment. The Mayo score consists of the following 4 subscores: stool frequency; rectal bleeding; endoscopy results; physician's global assessment. Each subscore~is rated on a scale from 0 (best) to 3 (worst). The total Mayo score is calculated as the sum of the 4 subscores and ranges from 0 (best) to 12 (worst)." (NCT00984568)
Timeframe: Up to Week 4

InterventionParticipants (Number)
Top-Hold10
Step-Up10

[back to top]

Number of Participants With Response at Week 4 and Steroid-Free Remission at Week 50

Response at Week 4 was defined as a minimum decrease from baseline in Mayo score of 3 points and 30%. Steroid-free remission at Week 50 was defined as a total Mayo score (including endoscopic assessment) of 2 points or lower and no individual subscore exceeding 1. The Mayo score consists of the following 4 subscores: stool frequency; rectal bleeding; endoscopy results; physician's global assessment. Each subscore is rated on a scale from 0 (best) to 3 (worst). The total Mayo score is calculated as the sum of the 4 subscores and ranges from 0 (best) to 12 (worst). (NCT00984568)
Timeframe: Week 50

InterventionParticipants (Number)
Top-Hold5
Step-Up5

[back to top]

Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population

PUCAI Score (0-85, sum of scores for each): abdominal pain (0/5/10 - no pain/ignored/not ignored), rectal bleeding (0/10/20/30 - none, small amount <50% of stools, small amount most stools, large amount >50%), stool consistency (0/5/10 - formed, partially formed, completely formed), # stools/24 hrs. (0/5/10/15 - 0-2/3-5/6-8/>8), nocturnal bowel/any diarrhea causing wakening (0/10 - no/yes), activity level (0/5/10 - no limitation/occ limitation, severe restrictions). Remission <10, Mild 10-34, Moderate 35-64, Severe 65-85. Remission defined as Treatment Success. (NCT01004185)
Timeframe: Week 26

Interventionpercentage of participants (Number)
High Dose53.3
Low Dose60

[back to top]

Treatment Success PUCAI Amended Endpoint (5 Point Scale Abdominal Pain), mITT

PUCAI Score (0-85, sum of scores for each) abdominal pain (0/2.5/5/7.5/10 - no pain/very mild/mild/moderate/severe), rectal bleeding (0/10/20/30 - none, small amount <50% of stools, small amount most stools, large amount >50%), stool consistency (0/5/10 - formed, partially formed, completely formed), # stools/24 hrs. (0/5/10/15 - 0-2/3-5/6-8/>8), nocturnal bowel/any diarrhea causing wakening (0/10 - no/yes), activity level (0/5/10 - no limitation/occ limitation, severe restrictions). Remission <10, Mild 10-34, Moderate 35-64, Severe 65-85. Remission is Treatment Success. (NCT01004185)
Timeframe: Week 26

Interventionpercentage of participants (Number)
High Dose60
Low Dose60

[back to top]

Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells After Treatment Crossover

Log(10) change in the percentage of activated T cells during the second 12 weeks of the study (NCT01090102)
Timeframe: Week 12, Week 24

InterventionLog10(percentage of T cells) (Mean)
Mesalamine Then Placebo0.003
Placebo Then Mesalamine-0.03

[back to top]

Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study

(NCT01090102)
Timeframe: Week 0, Week 12

InterventionLog10(percentage of T cells) (Mean)
Mesalamine Then Placebo0.03
Placebo Then Mesalamine-0.01

[back to top]